Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290693 | 1.00 | LMNA (0.50) | LMNAL3MBTL1PLA2G7FAAHNPC1 | |
| SCHEMBL12018747 | 1.00 | LMNA (0.50) | LMNAL3MBTL1PLA2G7FAAHNPC1 | |
| SCHEMBL7068296 | 0.86 | FAAH (0.44) | LMNAL3MBTL1PLA2G7FAAHNPC1 | |
| SCHEMBL3444780 | 0.80 | HCAR2 (0.58) | LMNAL3MBTL1PLA2G7NPC1RAB9A | |
| SCHEMBL3444775 | 0.80 | HCAR2 (0.58) | LMNAL3MBTL1PLA2G7NPC1RAB9A | |
| SCHEMBL3444778 | 0.80 | HCAR2 (0.58) | LMNAL3MBTL1PLA2G7NPC1RAB9A | |
| SCHEMBL15686743 | 0.77 | LMNA (0.46) | LMNAL3MBTL1PLA2G7NPC1RAB9A | |
| SCHEMBL22129143 | 0.77 | LTA4H (0.43) | LMNAL3MBTL1GAATAAR1MEN1 | |
| SCHEMBL4210427 | 0.77 | AKR1C3 (0.56) | PLA2G7NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL9709937 | 0.77 | LMNA (0.57) | LMNAL3MBTL1PLA2G7FAAHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | claimed |
| WO-2020055762-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2020-03-19 | — | — | WO | claimed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2020055762-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2020-03-19 | — | — | WO | disclosed |
| US-8632813-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | NEXMED (HOLDINGS), INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8227454-B2 | Estrogenic compounds, pharmaceutical compositions and formulations comprising the same | DURAMED PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110269725-A1 | NOVEL ESTROGENIC COMPOUNDS | HILL EDWARD N | 2011-11-03 | — | — | US | disclosed |
| US-7989436-B2 | Estrogenic compounds and pharmaceutical formulations comprising the same | DURAMED PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1464650-B1 | Novel estrogenic compounds, obtainable by heat treatment of conjugated estrogens in high humidity | BARR LAB INC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100234330-A1 | Novel Estrogenic Compounds | HILL EDWARD N | 2010-09-16 | — | — | US | disclosed |
| US-7749989-B2 | Estrogenic compounds, methods of using and methods of administering the same | DURAMED PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20040147496-A1 | Novel estrogenic compounds | DURAMED PHARMACEUTICALS, INC., | 2004-07-29 | — | — | US | disclosed |
| US-6660726-B2 | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same | ENDEAVOR PHARMACEUTICALS | 2003-12-09 | — | — | US | disclosed |
| EP-1359920-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Endeavor Pharmaceuticals (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030207855-A1 | Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention. | DURAMED PHARMACEUTICALS, INC., | 2003-11-06 | — | — | US | disclosed |
| EP-1263770-A1 | 6-OXYGENATED STEROIDAL ESTROGENS WITH AROMATIC A AND B RINGS | Endeavor Pharmaceuticals (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020107230-A1 | Methods and formulations for the treatment of female sexual dysfunction | BARR LABORATORIES, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002051420-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ENDEAVOR PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | disclosed |
| US-20020016316-A1 | Novel estrogenic compounds | DURAMED PHARMACEUTICALS, INC., | 2002-02-07 | — | — | US | disclosed |
| WO-2001068669-A1 | 6-OXYGENATED STEROIDAL ESTROGENS WITH AROMATIC A AND B RINGS | ENDEAVOR PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147496-A1 | Novel estrogenic compounds | HSD17B11, ESRRB, ESR2 | LMNA 4440/4885L3MBTL1 2844/4885PLA2G7 4018/4885 |
| US-20100234330-A1 | Novel Estrogenic Compounds | HSD17B11, ESR2, ESRRB | LMNA 3961/4885L3MBTL1 3005/4885PLA2G7 3955/4885 |
| US-20110269725-A1 | NOVEL ESTROGENIC COMPOUNDS | HSD17B11, ESR2, ESRRB | LMNA 3961/4885L3MBTL1 3005/4885PLA2G7 3955/4885 |
| US-20020016316-A1 | Novel estrogenic compounds | HSD17B11, ESRRB, ESR2 | LMNA 4347/4885L3MBTL1 2964/4885PLA2G7 4095/4885 |
| US-20030207855-A1 | Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention. | HSD17B11, CYP21A2, HSD17B13 | LMNA 3906/4885L3MBTL1 2728/4885PLA2G7 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.